A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.
Epithalon 2mg/mL
Investigational Pineal-Derived Tetrapeptide
Compound Specifications
Epithalon 2mg/mL
Investigational Pineal-Derived Tetrapeptide
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled after epithalamin and studied in cellular biology research for its potential interactions with telomerase reverse transcriptase (TERT) and pineal regulatory mechanisms. This is an investigational compound; these statements have not been evaluated by the FDA and it is not intended to diagnose, treat, cure, or prevent disease.
Preclinical literature suggests it may interact with chromatin structure, telomerase expression pathways, and pineal endocrine signaling involved in circadian biology. Results may vary; individual outcomes depend on baseline health, adherence, and other factors.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Short 10-20 day periodic biological rejuvenation cycles.
Frequently Asked Clinical Questions
How often are Epithalon protocols evaluated?
In research literature, protocols typically involve short periodic courses evaluated under healthcare provider oversight.